PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Genomic Health (GHDX) Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Genomic Health's (GHDX) escalating operating expenses dent bottom line in Q4.
Orthofix PhysioStim's FDA Nod and CE Mark Boosts Prospects
by Zacks Equity Research
Orthofix (OFIX) vouches for PhysioStim's efficiency, claiming the devices to lead the U.S. market of prescribed bone growth stimulators combined with spinal fusion stimulators.
Pacific Biosciences Unveils New Version of Sequel Software
by Zacks Equity Research
Pacific Biosciences (PACB) enhances performance and cost-effectiveness of the Sequel System.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) witnesses encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions in fourth-quarter 2017.
Quest Diagnostics Long-Term View Solid, Reimbursement a Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) upgraded long-term guidance based on its new and extended two-point strategy looks promising. However, it expresses resentment against the recent PAMA-related CMS proposal.
CryoLife (CRY) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
CryoLife (CRY) gains on growth in all the product lines along with a strong performance in all the geographies in Q4.
NuVasive Gains From International Business Amid Pricing Woes
by Zacks Equity Research
Sturdy performance of NuVasive's (NUVA) international business with more than 20% growth for the fifth consecutive quarter raises optimism among investors
Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit
by Zacks Equity Research
Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.
Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.
Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed
by Zacks Equity Research
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
Henry Schien to Distribute Grifols Product in United States
by Zacks Equity Research
We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.
Boston Scientific Acquires EMcision, Boosts Endoscopy Unit
by Zacks Equity Research
Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.
Abaxis Banks on Strong Veterinary Business Amid Margin Woes
by Zacks Equity Research
Abaxis' (ABAX) strong performance in Veterinary consumables drives growth. Weak gross and operating margin scenario is a concern.
Integra LifeSciences Banks on CSS Segment, Competition Rife
by Zacks Equity Research
Integra LifeSciences (IART) rides high on strength in the Codman Specialty Surgical segment.
Here's Why Teleflex Has Been Losing Ground Since Q4 Earnings
by Zacks Equity Research
Teleflex's (TFX) contracted Q4 adjusted operating margin is discouraging.
Bio-Rad (BIO) Q4 Earnings Improve Y/Y, Revenues Top Mark
by Zacks Equity Research
Bio-Rad's (BIO) strong sales in Q4 ride high on a robust performance at Life Science product lines.
Hologic's Alliance With Philips to Boost Breast Health Unit
by Zacks Equity Research
Hologic (HOLX) is consistently trying to fortify its Breast Health segment.
OPKO Health (OPK) Q4 Earnings Decline Y/Y, Margins Down
by Zacks Equity Research
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.
Medtronic's Guardian Sensor 3 With MiniMed 670G Wins FDA Nod
by Zacks Equity Research
Medtronic (MDT) advances with initiatives to boost the performance of its MiniMed portfolio.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.
Patterson Companies (PDCO) Misses on Q3 Earnings, Cuts View
by Zacks Equity Research
Lower sales and gross-margin compression mars Patterson Companies' (PDCO) results in Q3.
Masimo (MASI) Beats on Q4 Earnings & Revenues, View Positive
by Zacks Equity Research
Strong performance in Product revenues drove Masimo's (MASI) fourth-quarter 2017 results.
DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4
by Zacks Equity Research
DexCom (DXCM) rides high on strength in all segments in Q4.
Amedisys (AMED) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Amedisys (AMED) registers strong growth across all segments in Q4.
Express Scripts (ESRX) Q4 Earnings Top, Long-Term View Solid
by Zacks Equity Research
Express Scripts' (ESRX) fourth-quarter 2017 results benefit from rise in patient claims and strong customer retention.